SRPT - Sarepta Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
SRPT price evolution
SRPT
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $428.43 | $541.93 | $851.93 | $871.67 |
| Short term investments | $1247.82 | $1191.61 | $1008.79 | $1010.43 |
| Net receivables | $400.33 | $318.86 | $236.81 | $223.84 |
| Inventory | $514.23 | $420.12 | $393.51 | $366.82 |
| Total current assets | $2579.33 | $2450.85 | $2472.61 | $2488.38 |
| Long term investments | ||||
| Property, plant & equipment | $357.11 | $345.82 | $323.6 | $244.88 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $685.25 | $658.86 | $653.28 | $571.41 |
| Total investments | $1247.82 | $1191.61 | $1008.79 | $1010.43 |
| Total assets | $3264.58 | $3109.71 | $3125.89 | $3059.79 |
| Current liabilities | ||||
| Accounts payable | $164.92 | $87.95 | $109.8 | $106.71 |
| Deferred revenue | $487.42 | $507.49 | $529.99 | $552.24 |
| Short long term debt | $123.33 | |||
| Total current liabilities | $653.66 | $450.74 | $498.65 | $536.88 |
| Long term debt | $1273.48 | $1371.51 | $1364.69 | $1288.21 |
| Total noncurrent liabilities | $1751.58 | $1894.61 | $1885.83 | $1810.15 |
| Total debt | $1396.81 | $1371.51 | $1364.69 | $1288.21 |
| Total liabilities | $2405.24 | $2345.35 | $2384.48 | $2347.04 |
| Shareholders' equity | ||||
| Retained earnings | -$4446.21 | -$4491.87 | -$4450.93 | -$4426.99 |
| Other shareholder equity | $0.92 | -$0.64 | -$1.05 | -$0.42 |
| Total shareholder equity | $859.34 | $764.36 | $741.41 | $712.75 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $428.43 | $966.78 | $2115.87 | $1502.65 |
| Short term investments | $1247.82 | $1022.6 | $435.92 | |
| Net receivables | $400.33 | $259.7 | $152.99 | $101.34 |
| Inventory | $514.23 | $203.97 | $186.21 | $231.96 |
| Total current assets | $2579.33 | $2557.86 | $2604.1 | $2485.2 |
| Long term investments | ||||
| Property, plant & equipment | $357.11 | $244.99 | $236.69 | $282.19 |
| Goodwill & intangible assets | $7.58 | $14.24 | $13.63 | |
| Total noncurrent assets | $685.25 | $570.5 | $543.88 | $499.52 |
| Total investments | $1247.82 | $1022.6 | $435.92 | |
| Total assets | $3264.58 | $3128.37 | $3147.97 | $2984.72 |
| Current liabilities | ||||
| Accounts payable | $164.92 | $95.88 | $76.74 | $111.09 |
| Deferred revenue | $487.42 | $574.24 | $663.49 | $752.73 |
| Short long term debt | $123.33 | |||
| Total current liabilities | $653.66 | $619.6 | $452.73 | $416.03 |
| Long term debt | $1273.48 | $1544.29 | $1138.39 | $1072.86 |
| Total noncurrent liabilities | $1751.58 | $2123.81 | $1767.23 | $1806.93 |
| Total debt | $1396.81 | $1601.87 | $1138.39 | $1072.86 |
| Total liabilities | $2405.24 | $2743.42 | $2219.97 | $2222.96 |
| Shareholders' equity | ||||
| Retained earnings | -$4446.21 | -$3910.24 | -$3206.75 | -$2848.13 |
| Other shareholder equity | $0.92 | -$1.66 | -$0.02 | $0 |
| Total shareholder equity | $859.34 | $384.95 | $928.01 | $761.76 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $396.78 | $331.82 | $261.24 | $253.5 |
| Cost of revenue | $44.18 | $37.03 | $34.12 | $35.02 |
| Gross Profit | $352.61 | $294.79 | $227.11 | $218.48 |
| Operating activities | ||||
| Research & development | $195.52 | $194.3 | $241.89 | $245.68 |
| Selling, general & administrative | $131.7 | $120.89 | $118.56 | $110.71 |
| Total operating expenses | $327.98 | $315.63 | $360.63 | $356.57 |
| Operating income | $24.63 | -$20.84 | -$133.52 | -$138.09 |
| Income from continuing operations | ||||
| EBIT | $40.37 | -$33.17 | -$14.59 | -$512.71 |
| Income tax expense | -$5.28 | $7.76 | $9.36 | $4.04 |
| Interest expense | ||||
| Net income | ||||
| Net income | $45.66 | -$40.94 | -$23.94 | -$516.75 |
| Income (for common shares) | $45.66 | -$40.94 | -$23.94 | -$516.75 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1243.34 | $933.01 | $701.89 | $540.1 |
| Cost of revenue | $150.34 | $139.99 | $97.05 | $63.38 |
| Gross Profit | $1092.99 | $793.02 | $604.84 | $476.72 |
| Operating activities | ||||
| Research & development | $877.39 | $877.09 | $771.18 | $722.34 |
| Selling, general & administrative | $481.87 | $451.42 | $282.66 | $317.88 |
| Total operating expenses | $1360.82 | $1329.22 | $1064.55 | $1040.88 |
| Operating income | -$267.82 | -$536.2 | -$459.71 | -$564.16 |
| Income from continuing operations | ||||
| EBIT | -$520.1 | -$689.96 | -$418.95 | -$553.07 |
| Income tax expense | $15.88 | $13.53 | -$0.17 | $1.06 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$535.98 | -$703.49 | -$418.78 | -$554.13 |
| Income (for common shares) | -$535.98 | -$703.49 | -$418.78 | -$554.13 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $45.66 | -$40.94 | -$23.94 | -$516.75 |
| Operating activities | ||||
| Depreciation | $15.23 | $14.75 | $14.38 | $14.52 |
| Business acquisitions & disposals | -$4 | $102 | ||
| Stock-based compensation | $45.83 | $48.06 | $47.38 | $41.25 |
| Total cash flows from operations | -$54.66 | -$114.71 | -$122.23 | -$209.4 |
| Investing activities | ||||
| Capital expenditures | -$19.04 | -$29.67 | -$17.91 | -$9.48 |
| Investments | -$41.32 | -$169.8 | $12.59 | $22.07 |
| Total cash flows from investing | -$64.36 | -$210.57 | $96.63 | $12.49 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.94 | $15.4 | $5.86 | $28.04 |
| Net borrowings | ||||
| Total cash flows from financing | $1.94 | $15.4 | $5.86 | $101.8 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$117.07 | -$309.87 | -$19.74 | -$95.11 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$535.98 | -$703.49 | -$418.78 | -$554.13 |
| Operating activities | ||||
| Depreciation | $58.89 | $54.6 | $49.34 | $39.74 |
| Business acquisitions & disposals | $98 | $102 | $108.07 | |
| Stock-based compensation | $182.51 | $233.02 | $113.94 | $108.07 |
| Total cash flows from operations | -$500.99 | -$325.35 | -$443.17 | $107.47 |
| Investing activities | ||||
| Capital expenditures | -$76.11 | -$30.82 | -$38.49 | -$82.2 |
| Investments | -$176.46 | -$1013.63 | $436.01 | -$144.09 |
| Total cash flows from investing | -$165.8 | -$1046.88 | $495.41 | -$121.72 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $51.25 | $30.04 | $569.33 | $396.01 |
| Net borrowings | $303.45 | $291.11 | ||
| Total cash flows from financing | $125 | $232.51 | $561.57 | $682.32 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$541.79 | -$1139.72 | $613.81 | $668.07 |
News
Fundamentals
| Market cap | $10.98B |
|---|---|
| Enterprise value | $11.95B |
| Shares outstanding | 93.73M |
| Revenue | $1.24B |
|---|---|
| EBITDA | -$461.21M |
| EBIT | -$520.10M |
| Net Income | -$535.98M |
| Revenue Q/Q | 53.54% |
| Revenue Y/Y | 33.26% |
| P/E ratio | -20.48 |
|---|---|
| EV/Sales | 9.61 |
| EV/EBITDA | -25.90 |
| EV/EBIT | -22.97 |
| P/S ratio | 8.83 |
| P/B ratio | 12.79 |
| Book/Share | 9.16 |
| Cash/Share | 4.57 |
| EPS | -$5.72 |
|---|---|
| ROA | -17.07% |
| ROE | -69.66% |
| Debt/Equity | 2.80 |
|---|---|
| Net debt/EBITDA | -4.29 |
| Current ratio | 3.95 |
| Quick ratio | 3.16 |